↓ Skip to main content

Cochrane Database of Systematic Reviews

Budesonide versus placebo for chronic asthma in children and adults

Overview of attention for article published in Cochrane database of systematic reviews, October 1999
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news
3 news outlets

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
97 Mendeley
Title
Budesonide versus placebo for chronic asthma in children and adults
Published in
Cochrane database of systematic reviews, October 1999
DOI 10.1002/14651858.cd003274
Pubmed ID
Authors

Nick P Adams, Janine C Bestall, Paul Jones

Abstract

Inhaled budesonide is a widely used inhaled corticosteroid for asthma. The objectives of this review was to compare the efficacy of budesonide with placebo in the treatment of chronic asthma. The Cochrane Airways Group Trial Register and reference lists of articles was searched. We contacted trialists for additional studies and searched abstracts of major respiratory society meetings (1997-1999). Randomised trials in children and adults comparing budesonide to placebo in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. One reviewer extracted data. 43 studies met the inclusion criteria (2801 subjects). In non-oral steroid treated asthmatics, budesonide led to significant improvements in a number of measures of airway function. These included FEV1, Weighted Mean Difference (WMD) 3.7% predicted (95% CI 0.1, 7.2%); improvement in morning peak flow (PEF) from baseline WMD 29 L/min (95% CI 22, 36 L/min); improvement in evening PEF from baseline WMD 21 L/min (95% CI 13, 29 L/min). Varying methods of reporting symptoms limited the pooling of studies but all high methodological quality studies demonstrated significant improvements compared to placebo. Health status was not reported. Risk of trial withdrawal due to asthma exacerbation was lower with budesonide compared to placebo, relative risk 0.17 (95% CI 0.09, 0.33). Doses of 500-800 mcg/d appeared to have slightly larger effect sizes than lower doses, but no advantage for high doses were apparent. A single high quality RCT reported significant reductions in daily prednisolone requirement and the number of patients able to discontinue prednisolone completely in budesonide treated subjects compared to placebo. No difference in risk of oropharyngeal soreness/hoarseness or oral Candidiasis was apparent for budesonide compared to placebo. Long-term risk of adrenal insufficiency was not reported. This review strongly supports use of budesonide in chronic asthma. Consensus guidelines for chronic asthma suggest titrating inhaled steroid dose to individual requirements. Evidence from this review of trials does not present a case for routine dose titration above 800 mcg/d.

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Korea, Republic of 1 1%
United States 1 1%
Singapore 1 1%
Unknown 93 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 21%
Researcher 15 15%
Student > Bachelor 14 14%
Student > Ph. D. Student 7 7%
Other 7 7%
Other 12 12%
Unknown 22 23%
Readers by discipline Count As %
Medicine and Dentistry 43 44%
Nursing and Health Professions 12 12%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Psychology 4 4%
Agricultural and Biological Sciences 2 2%
Other 4 4%
Unknown 26 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2018.
All research outputs
#517,232
of 12,712,180 outputs
Outputs from Cochrane database of systematic reviews
#1,761
of 10,408 outputs
Outputs of similar age
#22,942
of 273,700 outputs
Outputs of similar age from Cochrane database of systematic reviews
#54
of 193 outputs
Altmetric has tracked 12,712,180 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,408 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.3. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,700 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 193 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.